ArticleBrachytherapy
Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy.
Article in Brachytherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Gantry-based pencil beam scanning proton therapy for uveal melanoma: IMPT versus proton arc therapy.Radiation oncology (London, England) · 2025Article
- Functional outcome after Brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.Radiation oncology (London, England) · 2025Article
- Proton Therapy in Uveal Melanoma.Cancers · 2024Review
- The prognostic implication of visual acuity at the time of uveal melanoma diagnosis.Eye (London, England) · 2023Article
- Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.Journal of contemporary brachytherapy · 2022Article
- CT-guided trans-sternal iodine-125 seeds implantation for masses in the anterior or middle mediastinum.Journal of contemporary brachytherapy · 2022Article
- Atypical choroidal nevus in a subject with a germline PALB2 pathogenic variant.Familial cancer · 2022Article
- Recent advancements in the management of retinoblastoma and uveal melanoma.Faculty reviews · 2021Review
- Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea.PloS one · 2020Article
- Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Magnetic resonance imaging metal artifact reduction for eye plaque patient with dental braces.Journal of contemporary brachytherapy · 2017Article
- Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.Ocular oncology and pathology · 2017Review
- Preparation, cytotoxicity, and in vivo antitumor efficacy ofInternational journal of nanomedicine · 2017Article
- Staged Eye-Plaque Brachytherapy: A Novel Approach for Large Uveal Melanoma.Advances in radiation oncologyArticle
- Prophylactic Intravitreal Bevacizumab After Plaque Radiotherapy for Uveal Melanoma: Analysis of Visual Acuity, Tumor Response, and Radiation Complications in 1131 Eyes Based on Patient Age.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Article
- Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma.BrachytherapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo report our experience in long-term follow-up of ocular melanoma patients treated with custom OSU-Nag eye plaques using (125)I sources.
methodsA retrospective chart review was conducted for 113 consecutive ocular melanoma patients with follow-up visual acuity data who were treated with OSU-Nag plaque episcleral brachytherapy at The Ohio State University Medical Center from 1994 to 2009. Visual acuity, complication data, and recurrence rates were recorded up to 120 months after brachytherapy.
resultsMedian age at presentation was 63.0 years (range, 22-93). Median follow-up was 65.5 months (range, 2-180). Median radiation dose at the prescription point was 85.8 Gy (range, 51.8-103.7). Preservation of useful visual acuity, defined as better than 20/200, was noted in 43 of 74 (58%) of patients in the present study at 36 months compared with 50.1% of Collaborative Ocular Melanoma Study participants. By 120 months, 17 of 30 (57%; 95% confidence interval, 45-69%) progressed to visual acuity worse than 20/200, whereas 9 of 30 (30%) retained visual acuity of 20/40 or better, and 4 of 30 (13%) were 20/50-20/200. The rate of retinopathy after radiation was approximately 40% of all those observed by 60 months. Baseline visual acuity, apical tumor height, American Joint Committee on Cancer tumor category, and distance between the tumor and the fovea were all significantly associated with loss of visual acuity. The local tumor control rate by 60 months of follow-up was 93% (95% confidence interval, 85-97%).
conclusionsThe OSU-Nag custom (125)I plaque is an effective treatment for uveal melanoma, with preservation of useful visual acuity in 58% of eyes 3 years after treatment and 43% of eyes 10 years after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.